Collectively, the results suggested that the interruption of the 5-HT/β-catenin/ZBP-89/TPH1 signaling loop by the THP1 inhibitor PCPA efficiently improved the outcome of prostate cancer therapy; this finding constitutes a novel perspective in tumor treatment. This evidence concerns the gene TPH1 and neoplasm.